vector icon vector icon
Back
Message sent successfully
fugure icon fugure icon
Back to News & Events

Nurami seeks FDA, EU approval for soft tissue repair solution

linkedin email
Nurami seeks FDA, EU approval for soft tissue repair solution
Nurami Medical has recruited all the patients for a clinical trial on its product to repair soft tissue damaged during neurosurgery
Related content
Thursday, 07 Mar 2024
New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
Friday, 16 Feb 2024
First ArtiFascia Dura repair procedures carried out in the US
Click Here To See The Full Article
figure icon

Most popular

New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
Thursday, 07 Mar 2024
New article published on ArtiFascia: Neural tissue tolerance to synthetic dural mater graft implantation – read more!
First ArtiFascia Dura repair procedures carried out in the US
Friday, 16 Feb 2024
First ArtiFascia Dura repair procedures carried out in the US
Iron Nation invests in Nurami Medical
Thursday, 25 Jan 2024
Iron Nation invests in Nurami Medical
ArtiFascia® Receives 510K Clearance
Thursday, 10 Aug 2023
ArtiFascia® Receives 510K Clearance

Contact us

Israel
USA
Nurami Medical Ltd. HQ
Israel
Nurami Medical Ltd. HQ
36 Ha-Namal St., Haifa, Israel
Nurami Medical INC.
USA
Nurami Medical Inc.
2436 Emrick Boulevard,
Bethlehem, PA 18020, USA
Message sent successfully
Skip to content